KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $7.8 million.

  • Castle Biosciences' Free Cash Flow fell 5402.71% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year decrease of 2652.02%. This contributed to the annual value of $36.5 million for FY2024, which is 28984.78% up from last year.
  • Castle Biosciences' Free Cash Flow amounted to $7.8 million in Q3 2025, which was down 5402.71% from $11.6 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Free Cash Flow registered a high of $26.9 million during Q4 2021, and its lowest value of -$38.9 million during Q2 2021.
  • Moreover, its 5-year median value for Free Cash Flow was -$6.1 million (2021), whereas its average is -$2.3 million.
  • Examining YoY changes over the last 5 years, Castle Biosciences' Free Cash Flow showed a top increase of 274180.57% in 2021 and a maximum decrease of 48335.55% in 2021.
  • Over the past 5 years, Castle Biosciences' Free Cash Flow (Quarter) stood at $26.9 million in 2021, then plummeted by 128.93% to -$7.8 million in 2022, then surged by 289.98% to $14.8 million in 2023, then increased by 13.55% to $16.8 million in 2024, then plummeted by 53.58% to $7.8 million in 2025.
  • Its Free Cash Flow was $7.8 million in Q3 2025, compared to $11.6 million in Q2 2025 and -$10.8 million in Q1 2025.